The economic value of a quadrivalent versus trivalent influenza vaccine.
The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.
Public Health Computational and Operations Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States. BYL1@pitt.edu
Bruce Y
BY
Lee
Sarah M
SM
Bartsch
Alyssa M
AM
Willig
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000191:economics* / Q000276:immunology*; D007251:Influenza, Human / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D007252:Influenza Vaccines